Nigerian
biotech startup Syndicate Bio has partnered SOPHiA GENETICS, a cloud-native
software company in the healthcare space and a leader in data-driven medicine,
to become the first lab in Africa to make comprehensive genomic profiling and
liquid biopsy widely available to patients throughout the entire continent.
Launched
in September by Dr Abasi Ene-Obong, previously founder and CEO of the
now-defunct Nigerian genomics startup 54gene, alongside Dr Jumi Popoola and
Estelle Dogbo, Syndicate Bio is leveraging collaborations with governments,
pharmaceutical companies, academia and other key industry stakeholders to
deepen local precision medicine impact while generating invaluable datasets
that improve global health outcomes and accelerates drug discovery and
development.
The
company, which in November announced a strategic partnership with the National
Institute for Cancer Research and Treatment (NICRAT) to initiate the Cancer
Genome Nigeria project. The implementation of the new genomic profiling and
liquid biopsy technology will further existing work from SOPHiA GENETICS,
Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health
equity on a global scale.
“Partnering
with SOPHiA Genetics to bring MSK-ACCESS powered with SOPHiA DDM to our lab is
a monumental step in accelerating the cancer treatment and research landscape
across Africa, beginning in Nigeria. Next-generation sequencing technologies in
oncology and liquid biopsy, which this collaboration enables, hold the
potential for creating a leapfrogging opportunity in the oncology treatment and
research landscape in Africa,” said Ene-Obong.
“Through
this collaboration, we aim to enable the widespread application of precision
medicine in oncology across Africa, and thus contributing to the improvement of
patient outcomes across the African continent. We believe our scientific
expertise, combined with AI-enabled technologies and data-driven solutions
enabled by SOPHiA GENETICS, presents a unique opportunity to fundamentally
transform the journey of cancer patients through non-invasive cancer analysis,
predictive genetic testing, and effective precision medicine.”
Leave Comments